PGEN — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-04

• In the second quarter of 2026, we achieved profitability from continuing operations for the first time since our strategic transformation into a healthcare company in 2020, marking a pivotal milestone in our evolution. Prior to this quarter, we have incurred significant losses since our inception. A…

• During the fourth quarter of 2025, we commenced commercial sales of Papzimeos, our FDA-approved immunotherapy for RRP. Revenues generated from Papzimeos during 2025 were limited, primarily due to the timing of the product’s commercial launch late in the year. Looking ahead, we expect that the majori…

• As we continue to transition to a commercial‑stage company, our future revenues will increasingly depend on our ability to successfully commercialize Papzimeos, advance our proprietary programs, and bring additional products enabled by our technology platforms to market.

• In addition, Exemplar generates product and service revenues through the development and sale of genetically engineered miniature swine models. We recognize revenue when control of the promised product or service is transferred to the customer. In 2025, revenues generated by Exemplar became less sig…

• We do not anticipate that we will be recognizing material collaboration revenue in the near term, except in cases of future strategic transactions involving our platforms or programs. Should new collaboration agreements or strategic transactions be executed, revenue could be impacted.

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• We have incurred significant losses since our inception. We may continue to incur losses in the foreseeable future, and we may never achieve or maintain profitability. Our historical collaboration and licensing revenues were generated under a business model from which we have transitioned. We may en…

• As we continue our efforts to focus our business and generate additional capital, we may be willing to enter into transactions involving one or both of our reporting units for which we have goodwill and/or intangible assets. These efforts could result in us identifying impairment indicators or recor…

• During the fourth quarter of 2025, we commenced commercial sales of Papzimeos, our FDA-approved immunotherapy for RRP. Revenues generated from Papzimeos during 2025 were limited, primarily due to the timing of the product’s commercial

• launch late in the year. Looking ahead, we expect that the majority of our future revenues will be derived from sales of Papzimeos as we continue to expand our commercial activities and market presence.

• As we transition to a commercial‑stage company, our future revenues will increasingly depend on our ability to successfully commercialize Papzimeos, advance our proprietary programs, and bring additional products enabled by our technology platforms to market.

Text added vs the prior filing · source: 10-Q · 2026-08-04

• In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures,

• no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

• In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that

• management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

• Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we carried out an evaluation, under supervision and with the participation of our management, including our Chief Executive Officer ("CEO"), who is our principal executive officer, and our Chief Fi…

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we carried out an evaluation, under supervision and with the participation of our management, including our Chief Executive Officer ("CEO"), who is our principal executive officer, and our Chief Fi…

• There has been no change in our internal control over financial reporting during the three months ended March 31, 2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Text added vs the prior filing · source: 10-Q · 2026-08-04

• Modification (June 30, 2026) (1)Modification of existing Rule 10b5-1 trading arrangement for the sale of common stock to revise certain pricing terms applicable to future salesSeptember 28, 2026December 31, 2026477,260 (1)

• (1) The trading arrangement was originally entered into on December 31, 2025 and subsequently modified (a) on March 31, 2026 to increase the aggregate securities subject to sales under the trading arrangement to 477,260, and (b) on June 30, 2026 to revise certain pricing terms applicable to future s…

• The Rule 10b5-1 trading arrangements described above were adopted and pre-cleared in accordance with Precigen’s Insider Trading Policy and actual transactions made pursuant to such trading arrangements will be disclosed publicly in future Section 16 filings with the SEC. Other than as disclosed abov…

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• Amended to increase the number of shares covered by the plan (March 31, 2026, original plan entered into on December 31, 2025)Trading Plan for sale of common stockJune 29, 2026December 31, 2026477,260

• The Rule 10b5-1 trading arrangements described above were adopted and pre-cleared in accordance with Precigen’s Insider Trading Policy and actual transactions made pursuant to such trading arrangements will be disclosed publicly in future Section 16 filings with the SEC. Other than disclosed above, …